Track topics on Twitter Track topics that are important to you
COLORADO SPRINGS, CO -- (Marketwired) -- 08/10/15 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. Company specializing in cannabinoid based drug development, is proud to announce that the initial California products have been released through their agreement with the Cannabis Science Research Foundation. The initial release is for test marketing, and results will be used for additional large-scale rollouts. The CBIS Brand is being sold in multiple locations in California; there are currently at least three or four public and private dispensaries to acquire the products.
The website will be updated on a weekly basis as more California locations and more diverse CBIS Products come online. Current Public locations that CBIS California Products can be found are:
Hidden Leaf Organics 5009 Melrose Ave. Los Angeles, CA 90038 323.822.5135
Cannacanhelp Inc (Formerly CCIC) 6614 Ave 304 Goshen, CA 93227 5596514090
"We have had previous success with self-medicated patient usage and we expect much of the same from this day forth. We have received plenty of requests from self-medicating patients worldwide looking for treatments for all types of critical ailments. We are just relieved to get these initial products out there to get self-medicating patient feedback. We have plenty of diverse products to be released for many different ailment situations, as each self-medicating patient has their unique needs and desires for their personal ailments. We will be releasing various product dosages, various delivery methodologies, in various jurisdictions as regulatory stipulations permit. We look forward to releasing more information about additional products and locations as the information becomes available. Please feel free to contact me directly with any questions and special requests; our team is ready," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder Cannabis Science Inc., and the Cannabis Science Research Foundation.
The California new product releases are due to Cannabis Science signing a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF is responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives. The CSRF license distribution agreement is required to accommodate the committed focus CBIS has on its FDA drug development programs.
About Cannabis Science Research Foundation
The Cannabis Science Research Foundation, a non-profit organization, is a new source of hope for a world where countless medical conditions affect millions of people in the United States alone. It is not just any foundation; it is an institute bringing new findings about the endocannabinoid system to light using state of the art research. The findings from the research will help guide the Foundation and its partners to develop new products, enter the FDA, and perform clinical studies.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...